Background
==========

SCLC usually presents as a lung lesion or mediastinal lymphadenopathy. It can be classified as limited disease (confined to 1 lung with/without lymph nodes on the same side, which can potentially be treated within 1 radiation port) or extensive disease (in the contralateral lung, lymph nodes on the contralateral side and/or distant metastasis). It is very rare for SCLC to present as a pleural effusion only with no lung or mediastinal lesion \[[@b1-amjcaserep-16-912]--[@b3-amjcaserep-16-912]\]. We present the case of a patient with pleural effusion due to small cell carcinoma without any evidence of lung lesions.

Case Report
===========

A 77-year-old white male with a 60-pack year history of smoking, chronic obstructive pulmonary disease (stage IV), and asbestos exposure presented with shortness of breath and left lateral chest pain for 7 days. Admission vitals were: Temp: 99°F, BP: 110/70 mmHg, HR: 100/min RR: 18/min. On physical examination he was very short of breath, with a prolonged expiratory phase on chest auscultation. Laboratory results showed leukocytosis and a chest radiograph showed left-sided pleural effusion ([Figure 1](#f1-amjcaserep-16-912){ref-type="fig"}). CT chest with IV contrast showed a left-sided pleural effusion without any lung lesions or mediastinal lymphadenopathy. Thoracentesis was performed and fluid was sent for analysis. The fluid re-accumulated within 24 hours and a repeat thoracentesis was performed. Repeat CT chest/abdomen/pelvis, done immediately following thoracocentesis, did not show any masses or lymphadenopathy ([Figures 2](#f2-amjcaserep-16-912){ref-type="fig"}, [3](#f3-amjcaserep-16-912){ref-type="fig"}).

The fluid was found to have tumor cells positive for synaptophysin, weakly positive for CD56, and negative for chromogranin and CD45 ([Figures 4](#f4-amjcaserep-16-912){ref-type="fig"}, [5](#f5-amjcaserep-16-912){ref-type="fig"}). The immunostaining pattern, in conjunction with the cytomorphology, was consistent with small cell carcinoma.

The patient was referred to oncology service. However, due to his poor functional status (stage IV COPD with oxygen dependence and limited mobility) and patient preference, he was referred for hospice care.

Discussion
==========

Lung cancer is the leading cause of malignant pleural effusion, seen in about 7--15% of all lung cancer at some time during the course of the illness \[[@b4-amjcaserep-16-912]--[@b6-amjcaserep-16-912]\]. Pleural effusions occur most frequently with adenocarcinoma \[[@b7-amjcaserep-16-912]\].

SCLC occurs most commonly in heavy smokers and usually presents as a mass in the central airways, such as near the hilum of the lung, or as a mediastinal lesion with accompanying adenopathy \[[@b8-amjcaserep-16-912],[@b9-amjcaserep-16-912]\]. It has particular propensity to spread to the liver, adrenal glands, bone, bone marrow, and brain \[[@b9-amjcaserep-16-912]\]. It can also present as a paraneoplastic syndrome, including Lambert-Eaton syndrome, SIADH, or Cushing's syndrome \[[@b9-amjcaserep-16-912]\]. Extrapulmonary small cell carcinomas are rare \[[@b10-amjcaserep-16-912],[@b11-amjcaserep-16-912]\]. However, there have been reports of it in the esophagus, salivary glands, gastrointestinal tract, pancreas, cervix, uterus, urinary bladder, prostate, and skin \[[@b10-amjcaserep-16-912]--[@b12-amjcaserep-16-912]\]. Small cell carcinoma originating from the pleura or metastasizing to the pleura is very rare \[[@b1-amjcaserep-16-912],[@b13-amjcaserep-16-912]\]. In 1 series, less than 3% of patients with SCLC had significant pleural effusion (requiring thoracocentesis) \[[@b1-amjcaserep-16-912]\]. In another series, 2--7% of patients with SCLC had pleural effusions, but the number of isolated pleural effusions was not reported \[[@b8-amjcaserep-16-912]\]. There are some reported cases of pleural masses, biopsy of which showed small cell carcinoma \[[@b14-amjcaserep-16-912]\]

In addition to recognition of SCLC cells in pleural effusion cytology based on morphology, immunohistochemistry has been proven to be very helpful in diagnosis \[[@b2-amjcaserep-16-912]\]. Chromogranin and synaptophysin are the markers commonly used to identify neoplastic cells of neuroendocrine origin. TTF-1 is also a sensitive marker for SCLC, with more than 90% reactivity \[[@b2-amjcaserep-16-912]\]. It may sometimes be difficult to morphologically differentiate neoplastic cells from lymphocytes, and immunohistochemistry can be invaluable in such instances \[[@b1-amjcaserep-16-912]\].

Despite being a rare presentation, survival of patients with SCLC presenting with isolated pleural effusion without any lung or mediastinal lesion is comparable to other patients with limited disease SCLC \[[@b3-amjcaserep-16-912],[@b15-amjcaserep-16-912]\]. Patients with limited disease SCLC are treated with combination chemotherapy (usually Cisplatin and Etoposide) and concurrent thoracic radiotherapy \[[@b16-amjcaserep-16-912]\]. However, treatment remains challenging because of SCLC's rapid growth, development of drug resistance during the course of the disease, and short disease-free duration following first-line chemotherapy \[[@b8-amjcaserep-16-912]\].

In our case, the patient presented with a left pleural effusion and no lung or mediastinal primary site was found. As mentioned above, this is extremely rare. Pleural fluid cytology and immunostaining pattern were suggestive of small cell lung carcinoma.

Conclusions
===========

Primary small cell lung cancer limited to the pleura and presenting as a pleural effusion without any underlying lung lesions is extremely rare. The present case underscores the importance of a good cytological examination along with advanced immunohistochemical markers on the pleural fluid. It also has implications for management, and isolated SCLC pleural effusion should be managed as limited-stage SCLC.
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